ArticleResearch square2026
Lupus myositis, a type I interferon driven necrotizing myopathy with regional heterogeneity.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lupus myositis (LM) is an underrecognized entity, whose pathological features significantly overlap with idiopathic inflammatory myopathies (IIMs). Currently, no standardized histopathological criteria or immunohistochemical (IHC) markers exist for the diagnosis of LM on muscle biopsy. We performed detailed histologic, immunohistochemical, ultrastructural, and spatial transcriptomic protein analyses on a stringent cohort of LM muscle biopsies, excluding patients with myositis-specific autoantibodies (MSA). Findings were compared with dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome (ASyS), and non-diseased control muscle specimens. Among 1736 patients diagnosed with systemic lupus erythematosus (SLE) between 2010 and 2023, 32 muscle biopsies were identified in myositis patients without MSA. Twenty-two cases demonstrated a necrotizing myopathy with spatial and temporal heterogeneity, MxA-positive myofiber expression, and perivascular inflammation composed of mixed T and B cells. A "pan-fascicular necrotizing myopathy" pattern was a highly recognizable feature of LM, although minority of cases demonstrated a diffuse scattered or perifascicular damage pattern. An IHC profile of MxA+/MHC I+/MHC II+ reliably distinguished LM from other IIMs. Spatial transcriptomics analysis confirmed that type I interferon pathway or MHC I related mRNAs and proteins were the most deferentially expressed in myofibers, capillaries and inflammatory cells. Electron microscopy identified frequent endothelial tubuloreticular inclusions. The remaining 10 cases demonstrated nonspecific myositis on muscle biopsy and were clinically associated with significant higher frequencies of overlapping systemic rheumatologic features such as interstitial lung disease, Sicca syndrome, systemic sclerosis, and rheumatoid arthritis, suggesting overlap myositis rather than pure LM. In conclusion, the pathological hallmark of LM is a type I interferon driven necrotizing myopathy with perivascular mixed T and B cell inflammation. A combined IHC panel including MxA, MHC I and MHC II effectively differentiates LM from other inflammatory myopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.